Felis ISSN 2398-2950

Grapiprant

Synonym(s): GalliprantĀ®

Contributor(s): Vetstream Ltd, Gigi Davidson

Introduction

Name

  • Grapiprant.

Class of drug

  • Prostaglandin E2 EP4 receptor antagonist (piprant).
  • Non-cycloxygenase inhibiting, non-steroidal anti-inflammatory drug.

Description

Chemical name

  • N-[[[2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4 methylbenzenesulfonamide.

Molecular formula

  • C26H29N5O3S

Molecular weight

  • 491.61

Physical properties

  • Beige to brown, flavored tablet.

Storage requirements

  • Store at or below 86° F (30° C).

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

With other drugs

  • Concurrent use with other anti-inflammatories has not been studied.
  • Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided.
  • Use with caution with other highly plasma protein bound drugs.

With diagnostic tests

  • Some dogs may develop decreased serum albumin and total protein.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed Papers

  • Recent references from VetMed Resource and PubMed.
  • Nagahisa A & Okumura T (2017) Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs. J Vet Thermacol 40(3), 285-292 PubMed.
  • Rausch-Derra L, Rhodes L (2016) Safety and toxicokinetic profiles associated with daily oral administration of grapiprant, a selective antagonist of the prostaglandin E2 EP4 receptor, to cats. Am J Vet Res 77(7), 688-692 PubMed.
  • Kirkby Shaw K, Rausch-Derra L & Rhodes L (2016) Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci 2, 3-9 PubMed.
  • Rausch-Derra L, Rhodes L, Freshwater L et al (2016) Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. J Vet Pharmcol Ther 40(3), 285-292 PubMed.
  • Rausch-Derra L, Huebner M, Wofford J et al (2016) A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. J Vet Int Med 30, 756-763 PubMed.
  • Rausch-Derra L, Huebner M & Rhodes L (2015) Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritis pain and inflammation, in healthy dogs. Am J Vet Res 76(10), 853-859 PubMed.

Other sources of information


ADDED